WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010033614) STABLE SOLID ORAL DOSAGE CO-FORMULATIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/033614    International Application No.:    PCT/US2009/057183
Publication Date: 25.03.2010 International Filing Date: 16.09.2009
IPC:
A61K 31/4965 (2006.01)
Applicants: SEQUOIA PHARMACEUTICALS [US/US]; 401 Professional Drive, Suite 100 Gaithersburg, MD 20879 (US) (For All Designated States Except US).
LUDTKE, Douglas [US/US]; (US) (For US Only).
DAGGER, Raymond [US/US]; (US) (For US Only)
Inventors: LUDTKE, Douglas; (US).
DAGGER, Raymond; (US)
Agent: BOOTH, Paul, M.; (US)
Priority Data:
61/097,479 16.09.2008 US
Title (EN) STABLE SOLID ORAL DOSAGE CO-FORMULATIONS
(FR) CO-FORMULATIONS DE DOSAGE ORAL SOLIDES STABLES
Abstract: front page image
(EN)Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed.
(FR)L'invention porte sur des compositions pharmaceutiques qui peuvent servir de stimulants pour améliorer la pharmacocinétique de médicaments qui subissent une dégradation in vivo par des enzymes du cytochrome P450. L'invention porte sur des procédés d'inhibition des enzymes du cytochrome P450 qui peuvent être utilisées pour améliorer le traitement de maladies par la prévention d'une dégradation de médicaments ou autres molécules par le cytochrome P450. Spécifiquement, l'invention porte sur des procédés consistant à inhiber une dégradation métabolique d'un sulfate d'atazanavir pour une administration à un patient souffrant d'une infection par le VIH.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)